Introduction:
Cyanide is a chemical warfare and toxic terrorism threat agent. Credible cyanide terrorism threats have been reported in Japan, the United States (Chicago, Illinois, eastern Texas, the 1991 World Trade Center bombing), New Zealand, the United Kingdom, Italy, the Middle East, and elsewhere. In addition, cyanide, like carbon monoxide, is a main toxicant contained in fire smoke.
A safe, efficacious antidote is required for use by prehospital responders. Of the antidotes available in the United States, sodium nitrite can cause life-threatening hypotension when administered too rapidly and can induce dangerous methemoglobinemia. Sodium thiosulfate alone acts too slowly. Hydroxocobalamin, a cyanide antidote with potential for use in the prehospital care setting, has been used in the prehospital setting for many years by the Brigade de Sapeurs-Pompiers de Paris (Paris Fire Brigade) in France.
Methods:
Published studies involving hydroxocobalamin as a cyanide antidote were reviewed for evidence of safety and efficacy, and the experience of the Paris Fire Brigade Service de la Sante was reviewed. Results: In in vitro and in vivo studies, hydroxocobalamin had efficacy similar to that of other available antidotes. In heavily smoking, normal, human volunteers, the administration of hydroxocobalamin was safe and efficacious in reducing low blood cyanide levels, although it was associated with a mild, transient elevation in blood pressure. Of 81 victims of smoke inhalation from enclosed-space fires in Paris, 18 of 29 who were in cardiac arrest recovered after hydroxocobalamin administration, and 12 of 15 with initial hypotension had clinical improvement. Adverse effects include transient dark red-brown discoloration of urine, skin, sclera, and mucous membranes from the color of the compound itself. Hypertension has not been observed in smoke-inhalation victims treated empirically for cyanide poisoning. Allergic reactions rarely have occurred with chronic low doses, but have not been reported following antidotal doses.
Discussion: Hydroxocobalamin has been used successfully in the prehospital setting. Even if the clinical diagnosis is incorrect, administering hydroxocobalamin is unlikely to result in harm. Hydroxocobalamin is a potentially useful product that could be administered safely when there is clinical suspicion of cyanide poisoning from either smoke inhalation or in a toxic terrorism mass-casualty situation. Conclusion: Hydroxocobalamin is the antidote of choice in France and has been shown to reduce cyanide levels with no apparent safety issues in vitro, in smokers, and in cyanide-poisoned victims in the prehospital setting. When analyzing the enhanced syndrome surveillance of the 2004 ADB Meeting in Jeju Island, Korea, the reporting rate was perfect (100%). The total number of patients was 7,833, and 1,401 (17.9%) syndromes were reported. There were seven episodes of aberration and, also, no proof of biological terror or outbreak of infectious diseases. Discussion: The enhanced syndrome surveillance system is a short-term, rapidly implemented, and event-specific system. It frequently includes active emergency department
